Background: Patients with advanced chronic obstructive pulmonary disease (COPD) or chronic heart failure (CHF) may experience significant symptom distress. For development of palliative care programs that adequately address symptoms of patients with COPD or CHF, it is necessary to know severity of symptom distress and to gain insight in comorbidities and current provision of health care. Objective of the present cross-sectional observational study was to assess severity of symptoms, presence of comorbidities, and current provision of health care in outpatients with advanced COPD or CHF. Methods: A total of 105 outpatients with clinically stable but advanced COPD (Global initiative for chronic Obstructive Lung Disease [GOLD] stage III or IV) and 80 patients with advanced CHF (New York Heart Association [NYHA] class III or IV) were assessed for demographics, clinical characteristics, self-reported comorbidities, and severity of symptoms using visual analogue scales. In addition, current health care and symptom-related interventions have been assessed. Results: Comorbidities were reported by 96.3% of the CHF patients and 61.9% of the COPD patients. Patients suffered from multiple symptoms, like dyspnea, fatigue, muscle weakness, coughing, low mood, sleeplessness, and frequent micturition. For most symptoms, only the minority of patients had received symptom-related treatment. Involvement of allied health care professionals was low. The majority of COPD and CHF patients had received home adaptation and medical aids. Conclusions: Patients with advanced COPD or CHF experience comorbidities and suffer from multiple symptoms, which are often under treated. Further development and implementation of palliative care programs, consisting of regular assessment of the patients' comorbidities and symptoms as well as the provision of patienttailored interventions is needed.
Introduction
C hronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) are major causes of morbidity and mortality worldwide. 1 The palliative care needs of patients with advanced COPD or CHF are increasingly being recognized. [2] [3] [4] Recent studies suggest that burden of symptoms in patients with advanced COPD or CHF is high and is associated with impairment of quality of life. [4] [5] [6] However, it remains unknown whether and to what extent the burden of symptoms is comparable between patients with advanced COPD and CHF. 7 In addition, little is known regarding symptom-related interventions and the current utilization of health care for patients with advanced COPD or CHF. A retrospective study of COPD patients in their last year of life suggests that the frequency of contact with health care professionals is low and that the care provided by health and social services is inadequate. 8 Furthermore, elderly COPD patients may receive less support from health care professionals and social services than similarly disabled persons without COPD. 9 For development of palliative care programs for patients with advanced COPD or CHF which adequately address symptoms, it is necessary to know the severity of symptoms, the presence of symptom-related interventions and utilization of health care.
Furthermore, while recent studies concerning symptom burden in COPD and CHF excluded patients with lifethreatening comorbidities, 5, 6 comorbidities in these patients may be common. 4, 10, 11 Presence of comorbidities may influence the palliative care needs and insight in the presence of comorbidities is necessary to understand how models of palliative care should be developed for these patients.
Therefore, the aim of the present study was to assess severity of symptoms, presence of comorbidities and current provision of health care in patients with advanced COPD or CHF.
We hypothesized a priori that comorbidities in advanced COPD or CHF are highly prevalent and that the experience of symptoms is similar, irrespective of the underlying disease. In addition, we hypothesized that symptoms are not adequately considered in treatment regimens for advanced COPD or CHF.
Methods

Design
This cross-sectional observational study is part of a longitudinal study concerning self-perceived symptoms and care needs in patients with severe to very severe COPD or CHF and the consequences for their closest relatives. 12 Details of the methodology of this study and data concerning advance care planning have been published before.
12,13
Study population
The study population consists of a convenience sample of outpatients with severe COPD or CHF. Patients were recruited by their physician specialist at the outpatient clinic of one academic and five general hospitals in The Netherlands in 2008 and 2009. Patients were eligible if they had a diagnosis of advanced COPD (Global initiative for chronic Obstructive Lung Disease [GOLD] stage III or IV) or advanced CHF (New York Heart Association [NYHA] class III or IV, as assessed by the referring cardiologist). For patients who were contacted for the study but refused participation, data including severity of disease, age and gender were collected in order to compare characteristics of participating and nonparticipating patients. All participating patients have given written informed consent. The Medical Ethical Commission of the Maastricht University Medical Centre þ (MUMCþ), Maastricht, the Netherlands, approved this study (MEC 07-3-054).
Instruments
Patients were visited by a member of the research team in their home environment. The following outcomes were assessed: demographics; weight and height; current selfreported comorbidities (Charlson Comorbidity Index  14 ) ; and forced expiratory volume in the first second (FEV 1 ). FEV 1 was calculated from the flow-volume curve measured by a handheld pulmonary spirometer. 15 NT-proBNP levels have been measured. NT-proBNP levels equal to or greater than 15 pmol/L may indicate the presence of CHF in COPD patients. 16 Severity of 20 self-perceived physical and psychological symptoms was assessed using a visual analogue scale (VAS) for every symptom. VAS is a horizontal straight line, ranging from 0 (no symptom) to 100 mm (maximum severity). 17 The patients had to mark on the line the point that represented the self-perceived severity of the symptom during the previous 2 weeks. The VAS score has been determined by measuring in millimeters from the left side of the line to the point the patient marked. 17 Symptoms were selected based on previous research. 7 The initial version of the VAS symptom checklist was reviewed by physician specialists of the project team and a physician specialist who was not involved in the project. Based on their expert opinion, several symptoms were added to the VAS symptom checklist.
In addition to rating severity of symptoms, patients were asked, if they had received symptom-related treatment (response options: ''yes'' or ''no'') for each reported symptom. Patients who reported that they received symptomrelated treatment had to rate their satisfaction with this treatment using VAS. VAS for satisfaction with treatment of the symptom ranged from 0 (not satisfied) to 100 mm (very satisfied).
In addition, symptoms of anxiety and/or depression were assessed using the Hospital Anxiety and Depression Scale (HADS), a validated and reliable measurement instrument used widely in medically ill patients to screen for clinically relevant symptoms of anxiety and/or depression. 18 The HADS is divided into an anxiety subscale (HADS-A) and a depression subscale (HADS-D). Total scores for each subscale can range from 0 (¼ optimal) to 21 (¼ worst) points. A score equal to or greater than 10 for anxiety and/or depression has been defined as abnormally high and may indicate the presence of clinically relevant symptoms of anxiety and/or depression. 18 Finally, use of medication, contacts with health care professionals (general practitioner, physician specialist, nurse, and allied health care professionals), use of long-term oxygen therapy, noninvasive positive pressure ventilation, home adaptation, and availability of medical aids were assessed using a health care checklist. Satisfaction with medical treatment was assessed using VAS.
The VAS symptom checklist and health care checklist are available from the authors upon request.
Statistics
All statistics were done using SPSS 17.0 (SPSS Inc., Chicago, IL). Categorical variables are described as frequencies, while continuous variables were tested for normality and are presented as mean and standard deviation (SD) or median and interquartile range (IQR). Categorical variables were compared between patients with COPD and CHF using w 2 tests. Continuous variables were compared between patients with COPD and CHF using an independent sample t test or MannWhitney U test, as appropriate. A priori, a two-sided level of significance has been set at p 0.05. 19 2 JANSSEN ET AL.
Results
General patient characteristics and comorbidities
In total, 105 COPD patients and 80 CHF patients were included. The proportion of eligible patients who participated in the study was 62.9% for COPD and 46.0% for CHF patients ( p < 0.05). Participating patients differed from patients who refused participation in some respects. COPD and CHF participants were younger than nonparticipants. Mean age of nonparticipants was 69.7 (9.7) years for COPD and 78.5 (9.0) years for CHF ( p < 0.05). In addition, COPD participants had more advanced disease than patients who refused participation. Only 38.7% of nonparticipants was classified as GOLD stage IV ( p < 0.05). Finally, CHF participants were more often male (67.5%) than nonparticipants (40.4%; p < 0.05).
Most COPD patients had very severe COPD (GOLD stage IV, n ¼ 77 [73.3%)). CHF patients were mainly classified as NYHA III (n ¼ 74, 92.5%). COPD patients were younger than CHF patients (Table 1 ). Comorbidities were reported by almost all CHF patients and the majority of COPD patients. The most frequently reported comorbidity was myocardial infarction (n ¼ 51, 63.8%) for CHF patients and diabetes (without end organ damage; n ¼ 20, 19.0%) for COPD patients (Table 1) . Nine COPD patients (8.6%) reported CHF as comorbidity, while 47 patients (46.1%) had a NT-proBNP level equal to or greater than 15 pmol/L, indicating the possible presence of CHF.
Severity of symptoms
Patients experienced multiple symptoms. The mean number of symptoms with VAS-score >30 mm (representing moderate severity 20 ) was comparable for COPD and CHF patients (8.1 [3.7) and 9.1 [3.5), respectively, p > 0.05). The number of experienced symptoms did not show a correlation with age (r ¼ 0.04, p ¼ 0.64).
Dyspnea, fatigue, and muscle weakness were the most severe symptoms in both diseases (Fig. 1) . The mean VAS score for dyspnea was higher for patients with COPD than CHF ( p < 0.05). Severe dyspnea (mean VAS score >54 mm 20 ) was reported by 57.1% of COPD patients.
Other important symptoms in both diseases were coughing, sleeplessness, low mood, and frequent micturition. Mean VAS scores for panic attacks, anxiety, oedema, mouth problems, muscle cramps, restless legs, angina pectoris, and dizziness were below 30 mm in both COPD and CHF. Prevalence of clinically relevant symptoms of anxiety was also similar between COPD patients (22.9%) and CHF patients (16.3%; p > 0.05). In addition, prevalence of clinically relevant symptoms of depression was similar for patients with COPD (27.6%) or CHF (25.0%; p > 0.05). Care provided by nurse specialist. Appproximately one third of the COPD patients (35.2%) received care from a respiratory nurse specialist, while the majority of CHF patients in this study (88.8%) received care from a heart failure nurse specialist. Only a minority of COPD patients (10.8%) were visited by their respiratory nurse specialist in their home environment, while 46.5% of the CHF patients were visited by their heart failure nurse specialist at home. Assistance with personal care was provided by professional caregivers in 21.9% of COPD patients and 40.0% of CHF patients ( p < 0.05). Relatives provided assistance with personal care in 22.9% of COPD patients and 20.0% of CHF patients ( p > 0.05).
Health care provision
Treatment by allied health care professionals. In general, involvement of allied health care professionals was low. Physiotherapy was more frequently offered to COPD patients (53.3%) than to CHF patients (30.0%; p < 0.05). Only a few patients received treatment from a dietician, psychologist, social worker, or occupational therapist (Fig. 2) . Indeed, 6.9% of the COPD patients and 10.0% of the CHF patients with clinically relevant symptoms of depression reported treatment by a psychologist ( p > 0.05).
Medical aids and home adaptation. Home adaptation was provided to 61.0% of COPD patients and 72.5% of CHF patients ( p > 0.05). Furthermore, 66.7% of COPD patients and 77.5% of CHF patients had medical aids ( p > 0.05). Adaptations at home most frequently offered were grab bars in bathroom or toilet, while the most frequently provided medical aids were rollators (Table 3) . However, despite the fact that many patients suffered from multiple symptoms, for most symptoms only a minority of patients were aware of symptom-related interventions. Furthermore, patients who reported symptom-related interventions were only moderately satisfied with these interventions (Table 4) .
Discussion
Key findings
The present study shows that comorbidities are highly prevalent in patients with advanced COPD or CHF. 
SYMPTOM DISTRESS IN ADVANCED COPD OR HEART FAILURE
Furthermore, patients with advanced COPD or CHF experience multiple symptoms. Attention for symptom management for these patients seems to be limited in current Dutch health care.
Comorbidities
The majority of clinically stable outpatients with advanced COPD or CHF report comorbidities. The high prevalence of COPD in CHF patients in the present study is in line with previous findings of Buist and colleagues 21 who showed high prevalence of COPD in the general elderly population. The mean FEV 1 of CHF patients shown in this study is in line with previous findings. 22 While only a few COPD patients report CHF as comorbidity, NT-proBNP levels suggest that about half of the patients with advanced COPD may have CHF. The concurrent existence of CHF in COPD patients has been shown before in elderly COPD patients. 10 This study shows that in patients with advanced COPD or CHF regular assessment of comorbidities is necessary.
Symptom distress and health care provision
Patients suffered from multiple symptoms including dyspnea, fatigue, muscle weakness, coughing, low mood, sleeplessness, and frequent micturition. The fact that fatigue and dyspnea are distressing symptoms in advanced COPD or CHF is in line with previous findings. 5, 6, 23 Previously, the retrospective study of Elkington and colleagues 8 suggested that health care is blind to the palliative care needs of COPD patients. The present prospective study shows that patients with advanced COPD or CHF suffer from multiple symptoms, while attention for symptom management seems to be limited. While in general patients are satisfied with their medical treatment, symptom distress is high and for most symptoms only a small minority of patients report that their symptoms are addressed. Furthermore, if symptoms are addressed, patients only report moderate satisfaction with symptom treatment. Therefore, the present study confirms the previous findings of Elkington and colleagues 8 in advanced COPD and CHF. A majority of the patients had infrequent contact with their general practitioner for their chronic disease. The infrequent general practitioner contact of the current sample suggest that general practitioners do not offer these patients treatment with an integrative and anticipatory approach. Therefore, it is unlikely that management of these patients in primary care focuses on prevention and early recognition and treatment of physical, psychosocial, and spiritual problems.
Only a few patients used medication for palliation of symptoms, like opioids. Although use of opioids for treatment of severe dyspnea in COPD is recommended in the most recent Official American Thoracic Society Clinical Policy Statement: Palliative Care for Patients with Respiratory Diseases and Critical Illnesses, 24 in the present study only 1.9% of COPD patients used strong opioids like morphine while 57.1% reported severe dyspnea. Au and colleagues 25 have shown in a retrospective study that only 25% of COPD patients in their last 6 months of life received opioids, while 49% of patients with lung cancer received opioids in their last 6 months of life. Randomized controlled trials regarding the use of opioids for the palliation of severe dyspnea in advanced COPD or CHF are scarce [26] [27] [28] and further research is needed to determine which patients should get opioids prescribed to treat their dyspnea. 29 Previous studies have shown that symptoms of depression are frequently undertreated in patients with COPD. 30, 31 This is supported by the present study. Only a minority of the patients with advanced COPD or CHF reporting clinically relevant symptoms of depression received counseling by a psychologist or used antidepressant drugs. In patients with Only patients who reported that they received treatment had to rate their satisfaction with treatment of the symptom.
COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; VAS, visual analogue scale.
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clinically relevant symptoms of depression, further assessment is warranted to identify those patients needing medical treatment for a depression. 31 Almost one third of the COPD patients used maintenance systemic corticosteroids, which is not in line with the currently available guidelines for management of COPD. 32 Physicians should pay careful attention to the use of maintenance oral corticosteroids. Indeed, systemic corticosteroids have been shown to be associated with lower limb muscle weakness and increased mortality risk. 33, 34 Care needs of patients with advanced COPD or CHF demand an interdisciplinary approach. 3, 24 Nevertheless, this study shows limited involvement of allied health care professionals. Provision of physiotherapy is highest for COPD patients, probably reflecting the Dutch physiotherapy guidelines for COPD. 35 However, symptoms such as muscle weakness and fatigue are also frequently reported by CHF patients, but only a minority of these patients are treated by a physiotherapist. This probably reflects a need for physical exercise training in patients with advanced CHF. 36, 37 Limitations of the present study
The study population consisted of a convenience sample of patients. While the majority of eligible COPD patients were willing to participate, the response rate for CHF patients was below 50%. The current response rate confirms the previously reported difficulty of recruitment of older patients with CHF 38 and may limit the generalizability of the results.
In addition, some differences were present between patients with COPD and CHF, which could have influenced the results of this study. Although age differences in this study are statistically significant, the clinical relevance for the present study may be limited, as is shown by the lack of correlation between number of experienced symptoms and age.
There is no consensus about standardization of symptom assessment in palliative medicine and multiple instruments are available. 39 We have chosen the use of VAS to assess severity of symptoms because of the previously shown validity, test-retest reliability and clinical utility. 17, 40 Furthermore, VAS is continuous, approximates a ratio scale, and is more independent from language than verbal scales. 41 However, the choice of the instrument might have influenced the results of this study.
Finally, the present study is a cross-sectional study and symptom distress and health care provision are likely to change during the course of the disease. A longitudinal follow-up is needed to know how symptom distress and health care provision change over time in patients with advanced COPD or CHF.
Conclusions and Implications
Patients with advanced COPD or CHF suffer from comorbidities and multiple symptoms. For most symptoms, only a minority of patients are aware of symptom-related interventions such as symptom-related medication and treatment by allied health care professionals. If treated, patients are only moderately satisfied with symptom treatment. While recent statements concerning palliative care for patients with COPD or CHF describe the need for offering palliative care concurrently with curative-restorative treatment during the course of the disease to adequately address symptoms and improve or maintain quality of life, 3, 24 the degree to which symptom management is addressed in current Dutch health care is limited. Further development and implementation of palliative care programs that consist of regular assessment of the patients' comorbidities and symptom distress is warranted. Future studies should assess the value of specialized interdisciplinary teams providing patient-tailored care to patients with advanced COPD or CHF.
